Lucentis (ranibizumab) is a prescription drug used to treat certain eye conditions. It comes as a liquid solution for injection into your eye by an ophthalmologist. The typical dosing frequency is ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

The US FDA has approved a new biosimilar of Roche and Novartis' blockbuster ophthalmology therapy Lucentis – Coherus BioSciences' Cimerli – which its developer claims is the first to be fully ...

Lucentis' main patents are not due to expire in Europe until next year, but Samsung Bioepis and Biogen are now poised to roll out the drug as soon the intellectual property on the drug lapses.

但「湿性」患者则可靠注射「血管内皮生长因子抑制剂」（Anti-VEGF，常见的药物有三种：Avastin、Lucentis、Eylea，还有一种为长效型类固醇Ozurdex ...

Lucentis, indicated for eye disorders, including wet age-related macular degeneration and diabetic retinopathy, is developed ...

a biosimilar of Lucentis®, in the Middle East region, including select territories of Jordan, Saudi Arabia, UAE, Iraq, Lebanon, and other GCC countries, the company announced through an exchange ...

The products—ReoPro, Lucentis and Cimzia—are used as treatments for cardiovascular, ophthalmic and immunological indications, respectively (Table 1). All three approved products are Fab molecules.

For example, in the UK, the National Institute for Health and Clinical Excellence (NICE) would only reimburse the use of Lucentis [ranibizumab, a humanized monoclonal antibody fragment that binds ...

Clinuvel says its share price weakness is typical of its peers. Meanwhile Opthea's trial timeline is on track and CMP is back ...

Mumbai: Global pharma major Lupin Limited has announced that it has received approval from the United States Food and Drug ...

Background: To identify differences between Ranibizumab and Aflibercept in treatment-naïve patients with neovascular age-related macular degeneration (nvAMD) in a real-life clinical setting ...